Trial Profile
Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients with Chronic Indeterminate Chagas Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Fexinidazole (Primary)
- Indications Chagas disease
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms FEXI12
- 01 Apr 2024 Results assessing(Between Oct 16,2017 and Aug 7,2018) efficacy and safety of fexinidazole at lower doses and for shorter treatment durations in this study were published in The Lancet Infectious Diseases.
- 10 Jan 2024 According to DNDi Foundation media release, data from this study published in The Lancet Infectious Diseases.
- 10 Jan 2024 Results published in the DNDi Foundation Media Release